Reducing versus discontinuing erythropoietin at high hemoglobin levels

Journal of the American Society of Nephrology

Volumn 18, Issue 12, 2007, Pages 3184-3191

  Weiner, Daniel E ^a   Miskulin, Dana C ^a   Seefeld, Kimberly ^a   Ladik, Vladimir ^b   Zager, Philip G ^c   Singh, Ajay K ^d   Johnson, H Keith ^e   Meyer, Klemens B ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b Keane Inc   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e Dialysis Clinic Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIESIS STIMULATING AGENT; ERYTHROPOIETIN; ERYTHROPOIETIN ALPHA; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALGORITHM; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG MEGADOSE; ERYTHROPOIESIS; FEMALE; GLOMERULONEPHRITIS; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLICY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

EID: 36849029259     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2007040477     Document Type: Article

References (25)

1. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, Benz RL: Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25: 548-554, 1995
2. Evans RW, Rader B, Manninen DL: The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 263: 825-830, 1990
3. Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE Jr: The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 7: 763-773, 1996
4. McClellan WM, Helgerson SD, Frederick PR, Wish JB, McMullan M: Implementing the Health Care Quality Improvement Program in the Medicare ESRD program: A new era of quality improvement in ESRD. Adv Ren Replace Ther 2: 89-94, 1995
5. Steinbrook R: Medicare and erythropoietin. N Engl J Med 356: 4-6, 2007
6. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 30[Suppl 3]: S192-S240, 1997
7. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 37[Suppl 1]: S182-S238, 2001
8. Ebben JP, Gilbertson DT, Foley RN, Collins AJ: Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 1: 1205-1210, 2006
9. Fishbane S, Berns JS: Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68: 1337-1343, 2005
10. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 47[Suppl 3]: S16-S85, 2006
11. Van Wyck DB: Update on the Anemia in CKD Guidelines. National Kidney Foundation 2007 Spring Clinical Meetings, Orlando, FL, April 12, 2007
12. Department of Health & Human Services (DHHS) Centers for Medicare & Medicaid Sen/ices (CMS). Pub 100-04 Medicare Claims Processing. National Monitoring Policy for EPO and Aranesp for End-Stage Renal Disease (ESRD) Patients Treated in Renal Dialysis Facilities. Nov 10, 2005. http://www.cms.hhs.gov/Transmittals/downloads/R751CP.pdf. Accessed March 2, 2007.
13. US Renal Data System. USRDS 2005 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, 2005
14. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA; The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
15. Drueke TB, Locatelli F, Clyne N, MacDougal IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
16. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
17. Hon G, Vaziri ND, Kaupke CJ, Tehranzadeh A, Barton C: Lack of a fast-acting effect of erythropoietin on arterial blood pressure and endothelin level. Artif Organs 19: 188-191, 1995
18. Kaupke CJ, Kim S, Vaziri ND: Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol 4: 1874-1878, 1994
19. Zhu X, Perazella MA: Nonhematologic complications of erythropoietin therapy. Semin Dial 19: 279-284, 2006
20. Department of Health and Human Services (DHHS) Health Care Financing Administration (HCFA). Change Request 2266: Modification of Medicare Policy for Erythropoietin (EPO), 2002
21. Ofsthun NJ, Lazarus JM: Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients. Blood Purif 25: 31-35, 2007
22. Collins AJ, Ebben JP, Gilbertson DT: EPO adjustments in patients with elevated hemoglobin levels: Provider practice patterns compared with recommended practice guidelines. Am J Kidney Dis 49: 135-142, 2007
23. Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernan MA: Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 297: 1667-1674, 2007
24. Rocco MV, Frankenfield DL, Hopson SD, McClellan WM: Relationship between clinical performance measures and outcomes among patients receiving long-term hemodialysis. Ann Intern Med 145: 512-519, 2006
25. US Renal Data System, USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, 2006